

## **European Contacts:**

Dom Maklerski WDM S.A. Email: <u>us@wdmcapital.com</u> Tel: (+48 71) 79 11 555

David Waldman or Justyna Gudaszewska Crescendo Communications Europe Sp. z.o.o

Email: mmd@crescendo-ir.com

## Milestone Medical Inc. Schedules Third Quarter 2014 Business Update Conference Call

**LIVINGSTON, NJ, November 12, 2014 -- Milestone Medical Inc. (WAR: MMD),** today provided a business update for the third quarter ended September 30, 2014.

The Board of Directors of Milestone Medical Inc. (the "Company") today announced that it will host a conference call at 3:00 p.m. Central European Time (9:00 a.m. Eastern Time), on Tuesday, November 18, 2014 to discuss the Company's financial results for the third quarter ending September 30, 2014, as well as the Company's progress and other significant developments.

The conference call can be accessed via a live Internet webcast on the Company's website at <a href="www.medicalmilestone.com">www.medicalmilestone.com</a>. A webcast replay of the conference call will be accessible on the Company's website at <a href="www.medicalmilestone.com">www.medicalmilestone.com</a> for 90 days. If investors have any questions that they would like to pose to management please email <a href="mailto:mmd@crescendo-ir.com">mmd@crescendo-ir.com</a> before 4:00 p.m. Central European Time on Friday, November 14, 2014.

## **About Milestone Medical Inc.**

Milestone Medical, Inc. has developed epidural and intra-articular drug delivery systems based on a patented, painless, computer-controlled injection and drug delivery technology originally developed by Milestone Scientific, Inc. Development of both the epidural and intra-articular instruments is now complete and the Company is currently pursuing regulatory approval for both instruments in the U.S. Milestone Medical, Inc. received CE Mark approval to sell and market its intra-articular and epidural instruments across European Union. For more information please visit www.medicalmilestone.com.

## Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.